<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713373</url>
  </required_header>
  <id_info>
    <org_study_id>I 274515</org_study_id>
    <secondary_id>NCI-2016-00228</secondary_id>
    <secondary_id>I 274515</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT02713373</nct_id>
  </id_info>
  <brief_title>Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of cetuximab when given together
      with pembrolizumab in treating patients with colorectal cancer that has spread from the
      primary site (place where it started) to other places in the body (metastatic) or that cannot
      be removed by surgery. Monoclonal antibodies, such as cetixumab and pembrolizumab, may block
      tumor growth in different ways by targeting certain cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the objective response rate of patients with metastatic colorectal cancer
      treated with pembrolizumab and cetuximab.

      II. To estimate the 6-month progression free survival (PFS) rate of patients with metastatic
      colorectal cancer treated with pembrolizumab and cetuximab.

      III. To examine the adverse event profile of combining pembrolizumab and cetuximab.

      SECONDARY OBJECTIVES:

      I. To examine the PFS of patients with metastatic colorectal cancer treated with
      pembrolizumab and cetuximab.

      II. To determine the objective response rate by immune-related response criteria (irRC) of
      patients with metastatic colorectal cancer.

      III. To examine the overall survival of patients with metastatic colorectal cancer treated
      with pembrolizumab and cetuximab.

      EXPLORATORY OBJECTIVES:

      I. Identify tumor and peripheral blood biomarkers of response and/or resistance to the study
      treatment.

      OUTLINE:

      Patients receive cetuximab intravenously (IV) over 120 minutes on day 1, 8, and 15 (as
      monotherapy for cycle 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment
      repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable
      toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience
      disease progression.

      After completion of the study treatment, patients are followed up every 3 months for up to 2
      years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2016</start_date>
  <completion_date type="Anticipated">January 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, categorized and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>The frequency of toxicities will be tabulated by maximum grade by preferred term within a patient across all cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS), evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>At 6 months</time_frame>
    <description>Will be tabulated and will be compared to the null values using exact tests. Distributions of PFS will be estimated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response rate, evaluated according to RECIST 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be tabulated and will be compared to the null values using exact tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response using immune-related RECIST</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to death, withdrawal of consent, or the end of the study, whichever occurs first, assessed up to 2 years</time_frame>
    <description>Distributions of OS will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At 6 months</time_frame>
    <description>PFS will be tested using an exact binomial test. Distributions of PFS will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in peripheral blood biomarkers using ELISA (enzyme linked immunosorbent assay).</measure>
    <time_frame>Day 1 of course 1 to up to day 1 of course 4 (12 weeks)</time_frame>
    <description>Pre- and post-treatment levels and changes from pre- to post-treatment in biomarkers will be summarized overall and by response and 6-month PFS categories using summary statistics (e.g., mean or median, with dispersion measures, and using transformed values as appropriate). Depending on the number of responses, logistic regression models may be used to compare response rates across pre-treatment biomarker levels. Proportional hazards models may be used to examine progression-free survival and overall survival across biomarker levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor biomarkers using immunohistochemistry</measure>
    <time_frame>Day 1 of course 1 to up to day 1 of course 4 (12 weeks)</time_frame>
    <description>Pre- and post-treatment levels and changes from pre- to post-treatment in biomarkers will be summarized overall and by response and 6-month PFS categories using summary statistics (e.g., mean or median, with dispersion measures, and using transformed values as appropriate). Depending on the number of responses, logistic regression models may be used to compare response rates across pre-treatment biomarker levels. Proportional hazards models may be used to examine progression-free survival and overall survival across biomarker levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor immune cell populations using flow cytometry</measure>
    <time_frame>Day 1 of course 1 to up to day 1 of course 4 (12 weeks)</time_frame>
    <description>Pre- and post-treatment levels and changes from pre- to post-treatment in biomarkers will be summarized overall and by response and 6-month PFS categories using summary statistics (e.g., mean or median, with dispersion measures, and using transformed values as appropriate). Depending on the number of responses, logistic regression models may be used to compare response rates across pre-treatment biomarker levels. Proportional hazards models may be used to examine progression-free survival and overall survival across biomarker levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in peripheral blood biomarkers using flow cytometry</measure>
    <time_frame>Day 1 of course 1 to up to day 1 of course 4 (12 weeks)</time_frame>
    <description>Pre and post treatment levels and changes form pre to post treatment in biomarkers will be summarized overall and by response and 6-month PFS categories using summary statistics (e.g., mean or median, with dispersion measures, and using transformed values as appropriate). Depending on the number of responses, logistic regression models may be used to compare response rates across pre-treatment biomarker levels. Proportional hazards models may be used to examine progression-free survival and overall survival across biomarker levels.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Recurrent Colorectal Carcinoma</condition>
  <condition>Stage IVA Colorectal Cancer</condition>
  <condition>Stage IVB Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (cetuximab and pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (cetuximab and pembrolizumab)</arm_group_label>
    <other_name>Chimeric Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody</other_name>
    <other_name>Chimeric MoAb C225</other_name>
    <other_name>Chimeric Monoclonal Antibody C225</other_name>
    <other_name>Erbitux</other_name>
    <other_name>IMC-C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cetuximab and pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (cetuximab and pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or
             otherwise unresectable

          -  Have received at least 1 prior systemic therapy in the metastatic or unresectable
             disease setting; patients who have recurred within six months of adjuvant chemotherapy
             are not required to have received an additional line of chemotherapy

          -  Retrovirus-associated deoxyribonucleic acid (DNA) sequence (RAS) wild-type; v-Ki-ras2
             Kirsten rat sarcoma viral oncogene homolog (KRAS) testing must be completed, with full
             KRAS and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) testing strongly
             advised; the presence of known mutations in KRAS or NRAS is exclusionary; primary
             tumor or metastatic tumor may be tested; (note: in the case of multiple genomic
             evaluations with conflicting results - e.g. KRAS mutant in one sample, but wild-type
             in another - the patient may be included as RAS wild-type, if clinically justified,
             after review with the principal investigator [PI])

          -  Naive to anti-EGFR therapy (cetuximab or panitumumab)

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
             criteria present

          -  Be willing to provide tissue from a newly obtained core or excisional biopsy of a
             tumor lesion; newly-obtained is defined as a specimen obtained up to 30 days prior to
             initiation of treatment on day 1; subjects for whom newly-obtained samples cannot be
             provided (e.g. inaccessible or subject safety concern) may submit an archived specimen
             only upon agreement from the principal investigator

          -  Hemoglobin &gt;= 8 g/dL (performed within 14 days of treatment initiation)

          -  Absolute neutrophil count &gt;= 1000/mm3 (performed within 14 days of treatment
             initiation)

          -  Platelet count &gt;= 100,000/mm3 (performed within 14 days of treatment initiation)

          -  Serum creatinine =&lt; 2 upper limit of normal (ULN) or, &gt;= 15 mL/min for participants
             with creatinine levels &gt; 2 ULN (performed within 14 days of treatment initiation)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5
             ULN or, =&lt; 5 ULN for participants with liver metastases (performed within 14 days of
             treatment initiation)

          -  Female participants of childbearing potential are to have a negative serum pregnancy
             test

          -  Female participants of child-bearing potential must agree to use an acceptable method
             of birth control, be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study medication;
             participants of childbearing potential are those who have not been surgically
             sterilized or have not been free from menses for &gt; 1 year; should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately

          -  Male participants must agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Participants who have had chemotherapy, targeted therapies, radiotherapy, or used an
             investigational device within 2 weeks prior to the first dose of treatment or those
             who have not recovered from adverse events (i.e., =&lt; grade 1 or at baseline) due to
             agents administered more than 2 weeks earlier; note: participants with =&lt; grade 2
             neuropathy are an exception to this criterion and may qualify for the study

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment

          -  Has a known history of active TB (Bacillus Tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients

          -  Has a known additional malignancy that requires active treatment; exceptions include
             basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has
             undergone potentially curative therapy or in situ cervical cancer

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis; participants with previously treated brain metastases may participate
             provided they are stable (without evidence of progression by imaging for at least four
             weeks prior to the first dose of trial treatment and any neurologic symptoms have
             returned to baseline), have no evidence of new or enlarging brain metastases, and are
             not using steroids for at least 7 days prior to trial treatment; this exception does
             not include carcinomatous meningitis which is excluded regardless of clinical
             stability

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form
             of systemic treatment

          -  Has known history of, or any evidence of active, non-infectious pneumonitis

          -  Uncontrolled clinically significant intercurrent illness including, but not limited
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, unstable cardiac arrhythmia, or psychiatric illness, substance abuse
             disorders or social situations that would limit compliance with study requirements

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Has a known history of human immunodeficiency virus (HIV or HIV 1/2 antibodies);
             testing not required

          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected); testing not required

          -  Has received a live vaccine within 30 days of planned start of study therapy (note:
             seasonal influenza vaccines for injection are generally inactivated flu vaccines and
             are allowed; however intranasal influenza vaccines (e.g., Flu-MistÂ®) are live
             attenuated vaccines, and shingles are not allowed)

          -  Received an investigational agent within 30 days prior to starting study treatment

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator

          -  Unwilling or unable to follow protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Boland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roswell Park</last_name>
      <phone>877-275-7724</phone>
      <email>askrpci@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Patrick M. Boland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Gortz, RN</last_name>
      <phone>216-844-1545</phone>
      <email>Janette.Grotz@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Eads</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

